Macfarlanes advises Advent Life Sciences on the closing of two new funds

22 February 2021

Macfarlanes has advised venture and growth capital firm Advent Life Sciences on the raising of two new life sciences-focused funds, Advent Life Sciences Fund III and the Advent-Harrington Impact Fund, which have closed with approximately €215m of investor commitments.

Investment commitments came from independent financial investors including international funds-of-funds, research foundations and family offices.

The funds will continue Advent Life Sciences’ investment strategy of identifying and backing high-impact, high-potential innovations that can deliver important new medicines for unmet medical needs.

The Macfarlanes team for this matter was led by investment management partner Chris Good with assistance from solicitors Sandeesh Shah and Catherine Born. Tax and reward expertise was provided by partner James McCredie and solicitor Joe Maughan

“LPs are looking more closely at life sciences and associated investment strategies at the current time,” commented Chris Good. “We are delighted to have helped Advent Life Sciences build out new LP relationships, despite the logistical challenges created by the Covid-19 pandemic.”